Endocyte Announces Vintafolide Plus Docetaxel Improved Overall Survival by 2.7 Months in NSCLC
September 07, 2015 at 15:50 PM EDT
Endocyte, Inc. (Nasdaq: ECYT), today presented the final overall survival (OS) analysis from the Phase 2b TARGET trial evaluating its ...
